IMF Videos Search Content For Care Partner (51) Patient (49) Healthcare Professional (37) Healthcare Provider (37) Series - Any - ASCO/EHA (16) ASH (10) Ask Dr. Durie (19) Black Swan Research Initiative (3) Community Workshops (3) Emerging Therapies (4) Facebook Live (2) Health Equity (3) IMWG (1) Living Well with Myeloma (3) Myeloma in a Minute (4) Myeloma Made Simple (3) Myeloma University (4) Patient & Family Webinar (1) Q&A (3) Recent News and Developments (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (19) High-Risk Myeloma (24) High-risk Smoldering Myeloma (12) Late Relapse (4–6 Lines of Therapy) (15) MGUS (14) Newly Diagnosed (Pre-Treatment or First Treatment) (69) Smoldering Myeloma (23) Types of Therapy Immunomodulatory drugs (IMiDs) (37) Immunotherapies (CAR T; BiTE, etc.) (22) Monoclonal antibodies (27) Proteasome inhibitors (31) Stem cell transplant (38) Steroids (28) Supportive Care (17) Year Published 2026 (6) 2025 (16) 2024 (19) 2023 (13) 2022 (3) 2021 (4) 2019 (5) 2018 (2) 2017 (4) 2016 (5) 2015 (4) Trusted Voices Dr. Brian GM Durie (20) Dr. Joseph Mikhael (20) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (6) Dr. Shaji Kumar (2) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. María-Victoria Mateos (1) Dr. Saad Usmani (1) Dr. Sigurður Kristinsson (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance 5 Multiple Myeloma Research Highlights: 2024 International Myeloma Society Meeting | For Patients October 17, 2024 Emerging Therapies Is Multiple Myeloma Hereditary? Myeloma in a Minute or Less October 10, 2024 Myeloma in a Minute Key Multiple Myeloma Abstracts Presented at 2024 ASCO and EHA Meeting August 1, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 28, 2024 ASCO/EHA Phase I Study: Dual Targeting BCMA & CD19 FASTCAR-T for High-Risk Multiple Myeloma June 27, 2024 ASCO/EHA Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Newly-Diagnosed Multiple Myeloma: GMMG-HD7 Interim Analysis June 24, 2024 ASCO/EHA IMROZ: Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma June 17, 2024 ASCO/EHA Isatuximab Plus Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma June 12, 2024 ASCO/EHA Improved Depth of Response and MRD Negativity with DARA + VRd in Transplant-Eligible NDMM: PERSEUS Trial Results June 10, 2024 ASCO/EHA What is the role of ASCT in the frontline setting for African-American patients? May 9, 2024 Ask Dr. Durie Is the face of myeloma changing? February 20, 2024 Ask Dr. Durie Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients January 31, 2024 ASH Load More
